Luke Halpern, Associate Editor

A real-world analysis of matched adults links glucagon-like peptide-1 (GLP-1) receptor agonist use to fewer major cardiovascular events, driven by a mortality benefit.

A minimum agreed set of outcomes could let pharmacists compare chronic kidney disease (CKD) interventions head-to-head and cut the heterogeneity that has long muddied trials.

Five "essential" outcomes, including medication error and adherence, should anchor every pharmacist intervention study in chronic kidney disease.

Glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 agents are just the start: amylin- and glucagon-based mono-, dual-, and tri-therapies are on the horizon.

A multicohort study finds divergent complication patterns and raises the prospect that millions are being treated for the wrong mechanism.

Pharmacists’ medication expertise can mitigate GI adverse effects and improve outcomes for patients beginning obesity pharmacotherapy

A Medicare GLP-1 bridge program marks 2026, while multiagonists like CagriSema are poised to lead the next wave of obesity therapy.

Rusfertide gives adults with polycythemia vera a first-in-class option to cut phlebotomy dependence and control hematocrit.

From enlicitide to Lp(a)-lowering siRNAs, a look at the add-on therapies helping high-risk patients reach stricter LDL targets below 55 mg/dL.

Pharmacist Jennifer Goldman on why expectation-setting, GI counseling, and nutrition drive glucagon GLP-1 persistence and long-term success.

Real-world data show sustained tirzepatide use offset its cost by 12 months in adults older than 55 years, with fewer hospital and ED visits.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

Brepocitinib (Lisraya), a once-daily TYK2-JAK1 inhibitor, is the first oral therapy approved for adults with the rare autoimmune disease.

If Heidi Overton is confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.

Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.

A diabetologist who lives with type 1 diabetes weighs in on real-time ketone monitoring and what it means for at-risk patients.

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.

New data show Opill reaches uninsured, rural, and younger patients—putting pharmacists at the center of daily dosing counseling.

Older triglyceride drugs manage only 10% to 30% reductions; newer injectables go far further, with FCS as their first key role.

Stacey Cutrell, PharmD, BCACP, CDCES, on the PREVENT calculator, screening for secondary causes, intensive BP targets, and fixing stubborn blood pressure.

Abbott's Libre Duo 10 Day tracks both glucose and ketones to flag rising DKA risk in people with diabetes 2 years and older.

The first single-biomarker blood test is cleared for both rule-in and rule-out of amyloid pathology in primary and specialty care.

Nipocalimab is the first therapy approved specifically for wAIHA, a rare, life-threatening autoantibody disease driving red blood cell destruction.

Tracking 3-year changes in the heart stress marker separated older adults whose risk climbed from those whose risk resolved.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists can spot metabolic dysfunction-associated steatotic liver disease (MASLD) risk, weigh GLP-1 and MASH therapies, and pair medication with lifestyle change.

Novo Nordisk's false-advertising case against Eli Lilly turns on GLP-1 dosing—here's the context pharmacists need when patients ask which drug is better.

Before escalating therapy, Stacey M. Cutrell, PharmD, urges pharmacists to rule out pseudo-resistance and nonadherence driving stubborn blood pressure.

Cardiomyopathy, hepatitis B, breast cancer, hypertension, and myeloma decisions land in the FDA's final-quarter queue.

Finerenone, SGLT2s, and GLP-1s each target a different driver of CKD—pharmacists can tie every drug to a matching lifestyle change for adherence.

Jeremy Johnson, PharmD, on how oral and injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are helping high-risk patients hit LDL targets statins alone can't reach.